Global Fund Secures Affordable Tuberculosis Test from Cepheid Amid Pressure Campaign

1 min read
Source: Danaher | Investor Overview
TL;DR Summary

Danaher Corporation has announced an agreement to provide Cepheid's Xpert® MTB/RIF Ultra diagnostic test cartridges for tuberculosis (TB) at cost to the Global Fund to Fight AIDS, TB and Malaria and less-developed countries eligible for Cepheid's Global Access Program. By reducing the price of the test cartridge to $7.97, Danaher will earn no profit. The agreement expands the partnership between Cepheid and the Global Fund, aiming to improve access to high-quality TB testing in countries where it is most needed. The Global Fund is the largest provider of financing and programs to combat TB globally.

Share this article

Reading Insights

Total Reads

0

Unique Readers

1

Time Saved

4 min

vs 5 min read

Condensed

90%

91695 words

Want the full story? Read the original article

Read on Danaher | Investor Overview